Aarti Drugs commences commercial production at Gujarat manufacturing plant
The facility will manufacture Dimethylamine, Monomethylamine, Trimethylamine, and their derivatives
Aarti Drugs has commenced the Commercial Production/ Commercial Operations at its new manufacturing plant situated at Sayakha, Gujarat with effect from September 4, 2025. The facility will manufacture Dimethylamine, Monomethylamine, Trimethylamine, and their derivatives.
The plant has a proposed capacity of 60 metric tonnes per day (MTPd). Currently, capacity utilization will be approximately one third of its total capacity. Plant will become fully operational over next 12 to 18 months. The company has invested around Rs 220 crore.
Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.
